Category: ACN Newswire

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open

– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters – The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a

More

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

ZUG, SWITZERLAND AND VILNIUS, LITHUANIA, Mar 4, 2025 – (ACN Newswire via SeaPRwire.com) – Micreos Pharmaceuticals AG (“Micreos”), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic

More